Serum vaspin may be a good indicator of fibrosis in chronic hepatitis C and is not altered by antiviral therapy

Polish Journal of Pathology

Volumn 63, Issue 4, 2012, Pages 213-220

  Kukla, Michał ^a   Marek, Waluga ^a   Tomasz, Sawczyn ^a   Agnieszka, Berdowska ^b   Maciej, Kajor ^a   Grzegorz, Boryczka ^a   Dominika, Stygar ^a   Andrzej, Gabriel ^a   Zwirska Korczala, Krystyna ^a   Marek, Hartleb ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b JAN DLUGOSZ UNIVERSITY   (Poland)

Author keywords

Adipokine; Antiviral therapy; Chronic hepatitis C; Fibrosis; Insulin resistance; Liver; Steatosis; Vaspin

Indexed keywords

ANTIVIRUS AGENT; BIOLOGICAL MARKER; SERINE PROTEINASE INHIBITOR; SERPINA12 PROTEIN, HUMAN;

ADULT; ARTICLE; BLOOD; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS C; HUMAN; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PATHOLOGY; VIROLOGY;

ADULT; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; SERPINS; YOUNG ADULT;

EID: 84873849688     PISSN: 12339687     EISSN: None     Source Type: Journal    
DOI: 10.5114/PJP.2012.32767     Document Type: Article

References (25)

1. Marra F, Bertolani C. Adipokines in liver diseases. Hepatology 2009; 50: 957-69.
2. Xu H, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003; 112: 1821-1830.
3. Fartoux L, Poujol-Robert A, Guéchot J, et al. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut 2005; 54: 1003-1008.
4. Yoneda M, Saito S, Ikeda T, et al. Hepatitis C virus directly associates with insulin resistance independent of the visceral fat area in nonobese and nondiabetic patients. J Viral Hepat 2007; 14: 600-607.
5. Adinolfi LE, Durante-Mangoni E, Zampino R, et al. Review article: hepatitis C virus-associated steatosis - pathogenic mechanism and clinical implications. Aliment Pharmacol Ther 2005; 22 (Suppl. 2): 52-55.
6. Mehta SH, Brancati FL, Sulkowski MS, et al. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 2000; 133: 592-599.
7. Perlemuter G, Sabile A, Letteron P, et al. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viralrelated steatosis. FASEB J 2002; 16: 185-194.
8. Hui JM, Sud A, Farrell GC, et al. Insulin resistance is associated with chronic hepatitis C infection and fibrosis progression. Gastroenterology 2003; 125: 1695-1704.
9. Romero-Gómez M, Del Mar Viloria M, Andrade RJ, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005; 128: 636-641.
10. Hung CH, Wang JH, Hu TH, et al. Insulin resistance is associated with hepatocellular carcinoma in chronic hepatitis C infection. World J Gastroenterol 2010; 16: 2265-2271.
11. Douglas MW, George J. Molecular mechanisms of insulin resistance in chronic hepatitis C. World J Gastroenterol 2009; 15: 4356-4364.
12. Klöting N, Berndt J, Kralisch S, et al. Vaspin gene expression in human adipose tissue: association with obesity and type 2 diabetes. Biochem Biophys Res Commun 2006; 339: 430-436.
13. Wada J. Vaspin: a novel serpin with insulin-sensitizing effects. Expert Opin Investig Drugs 2008; 17: 327-333.
14. Rabe K, Lehrke M, Parhofer KG, Broedl UC. Adipokines and insulin resistance. Mol Med 2008; 14: 741-751.
15. Kukla M,Zwirska-Korczala K, Gabriel A, et al. Chemerin, vaspin and insulin resistance in chronic hepatitis C. J Viral Hepat 2010; 17: 661-667.
16. Scheuer PJ. The nomenclature of chronic hepatitis: time for a change. J Hepatol 1995; 22: 112-114.
17. Brunt EM, Janney CG, Di Bisceglie AM, et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-2474.
18. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-1321.
19. Seeger J, Ziegelmeier M, Bachmann A, et al. Serum levels of the adipokine vaspin in relation to metabolic and renal parameters. J Clin Endocrinol Metab 2008; 93: 247-251.
20. Kukla M, Mazur W, Bułdak RJ, et al. Potential role of leptin, adiponectin and three novel adipokines - visfatin, chemerin and vaspin - in chronic hepatitis. Mol Med 2011; 17: 1397-1410.
21. El-Mesallamy HO, Kassem DH, El-Demerdash E, et al. Vaspin and visfatin/Nampt are interesting interrelated adipokines playing a role in the pathogenesis of type 2 diabetes mellitus. Metabolism 2011; 60: 63-70.
22. Kukla M, Zwirska-Korczala K, Hartleb M, et al. Serum chemerin and vaspin in non-alcoholic fatty liver disease. Scand J Gastroenterol 2010; 45: 235-242.
23. Gabriel A, Kukla M, Ziolkowski A. Histopathological features and current scoring systems for semiquantitative assessment of nonalcoholic fatty liver disease. Exp Clin Hep 2008; 4: 48-54.
24. Aktas B, Yilmaz Y, Eren F, et al. Serum levels of vaspin, obestatin, and apelin-36 in patients with nonalcoholic fatty liver disease. Metabolism 2011; 60: 544-549.
25. Adinolfi LE, Gambardella M, Andreana A, et al. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33: 1358-1364.